SOPHiA GENETICS S.A. (SOPH) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SOPH Revenue Growth
Revenue Breakdown
SOPH's revenue distribution by segment and geography
By Geography
SOPH Revenue Analysis (2019–2025)
As of May 8, 2026, SOPHiA GENETICS S.A. (SOPH) generated trailing twelve-month (TTM) revenue of $81.2 million, reflecting exceptional growth of +22.0% year-over-year. The most recent quarter (Q1 2026) recorded $21.7 million in revenue, down 0.1% sequentially.
Looking at the longer-term picture, SOPH's 5-year compound annual growth rate (CAGR) stands at +22.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $77.3 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including NTRA (+35.9% YoY), EXAS (+17.7% YoY), and VCYT (+16.9% YoY), SOPH has underperformed the peer group in terms of revenue growth. Compare SOPH vs NTRA →
SOPH Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SOPHCurrent | $81M | +22.0% | +22.2% | -91.8% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 VCYT | $517M | +16.9% | +34.5% | 14.3% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% |
SOPH Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $77.3M | +18.6% | $47.8M | 61.9% | $-70,925,000 | -91.8% |
| 2024 | $65.2M | +4.5% | $43.9M | 67.4% | $-66,568,000 | -102.1% |
| 2023 | $62.4M | +31.1% | $42.9M | 68.8% | $-74,826,000 | -120.0% |
| 2022 | $47.6M | +17.6% | $31.3M | 65.7% | $-87,823,000 | -184.7% |
| 2021 | $40.5M | +42.4% | $25.2M | 62.4% | $-71,489,000 | -176.7% |
| 2020 | $28.4M | +12.0% | $17.7M | 62.3% | $-37,387,000 | -131.6% |
| 2019 | $25.4M | - | $17.8M | 70.3% | $-32,287,000 | -127.3% |
See SOPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SOPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SOPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSOPH — Frequently Asked Questions
Quick answers to the most common questions about buying SOPH stock.
Is SOPH's revenue growth accelerating or slowing?
SOPH revenue is accelerating at +22.0% year-over-year, exceeding the 5-year CAGR of +22.2%. TTM revenue reached $81M. Growth momentum has increased versus prior periods.
What is SOPH's long-term revenue growth rate?
SOPHiA GENETICS S.A.'s 5-year revenue CAGR of +22.2% reflects the sustained expansion pattern. Current YoY growth of +22.0% is above this long-term average.
How is SOPH's revenue distributed by segment?
SOPH reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.